CLINICAL OUTCOMES OF INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
DOI:
https://doi.org/10.5281/zenodo.17233238Keywords:
Non-muscle invasive bladder cancer, intravesical chemotherapy, mitomycin C, doxorubicin, epirubicin, recurrence, progressionAbstract
Non-muscle invasive bladder cancer (NMIBC) is characterized by a high recurrence rate and risk of progression. In settings where Bacillus Calmette–Guérin (BCG) immunotherapy is not available, intravesical chemotherapy remains the cornerstone of adjuvant treatment. However, data comparing different chemotherapeutic agents in routine practice remain limited.
References
Бойко Е.В., Алламова Ш.М. Значение ангиогенеза в прогнозировании рецидива немышечно инвазивного рака мочевого пузыря. Доктор ахборотномаси № 3 (115)—2024, DOI: 10.38095/2181-466X-20241153-159-162
Бойко Е.В., Алламова Ш.М. Прогностическое значение ангиогенеза при немышечно-инвазивном раке мочевого пузыря. Журнал медицина и инновации №3 (15) – 2024, ISSN 2181-1873, 129-139
Babjuk, M., Burger, M., Compérat, E., Gontero, P., Mostafid, A. H., Palou, J., van Rhijn, B. W., Rouprêt, M., Shariat, S. F., Sylvester, R., Zigeuner, R., & Capoun, O. (2022). European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and CIS). European Urology, 81(1), 75–94. https://doi.org/10.1016/j.eururo.2021.08.010
Cambier, S., Sylvester, R. J., Collette, L., Gontero, P., Brausi, M. A., van Andel, G., & others. (2016). EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette–Guérin. European Urology, 69(1), 60–69. https://doi.org/10.1016/j.eururo.2015.06.045
Sylvester, R. J., Oosterlinck, W., & van der Meijden, A. P. M. (2004). A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. Journal of Urology, 171(6), 2186–2190. https://doi.org/10.1097/01.ju.0000125486.92260.b2
